At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Ipilimumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Preoperative Pilot Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable (HCC)
In Brief
A Phase 2 clinical trial evaluating Ipilimumab and Nivolumab for Hepatocellular Carcinoma and Resectable Hepatocellular Carcinoma. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This phase II trial studies the side effects and how well nivolumab with or with ipilimumab works in treating patients with liver cancer that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartSep 2017
Primary CompletionSep 2022
TodayJul 2026
First PostedJul 19, 2017
Enrollment StartSep 28, 2017
Primary CompletionSep 14, 2022
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 9.0 years ago
Interventions
Ipilimumabbiological
Given IV
Nivolumabbiological
Given IV